Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a special screen light reduce tired eyes and dryness?

NCT ID NCT07706231

Symptom relief Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This study tests whether a full-spectrum screen bar light can reduce eye fatigue and dry eye symptoms after two hours of computer work. Healthy adults aged 18 to 35 who use screens at least four hours daily will be randomly assigned to use the light or a standard screen without it. Researchers will measure changes in eye fatigue, blinking, tear film, and dry eye symptoms before and after the task.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
full-spectrum screen bar light
What this could lead to
If effective, this lighting could offer a simple way to reduce eye strain and dryness for people who spend long hours at screens.
What could go wrong
This is a small, early-stage lab study with 112 participants, so results may not apply to real-world settings or all screen users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 112 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 to 35 years, male or female. 2. Average daily electronic screen exposure of at least 4 hours. 3. Near visual acuity at 40 cm of 0.5 or better, and able to complete the study 1. tasks and measurements stably. 4. Able and willing to provide written informed consent. Exclusion Criteria: 1. Presence of ocular inflammation or ocular disease. 2. History of severe systemic disease, neurological disease, or psychiatric disorder. 3. Pregnancy or lactation. 4. Use of dry eye or visual fatigue treatments, or contact lens wear, within 1 month before the study. 5. History of ocular surgery within the past 6 months. 6. Daily use of lenses with blue-light blocking, photochromic, polarized, filtering, or similar optical functions. 7. Professional background in ophthalmology or optical products. 8. Intake of caffeine or other stimulants within 4 hours before the study. 9. Best-corrected visual acuity (BCVA) less than 0.8. 10. Anisometropia of 1.00 diopter or greater, or astigmatism of ±2.00 diopters or greater. 11. Intraocular pressure (IOP) less than 5 mmHg or greater than 21 mmHg. 12. Non-invasive tear breakup time (NIBUT) less than 5 seconds in either eye. 13. Ocular Surface Disease Index (OSDI) score of 33 or greater.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Computer vision syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthenopia dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Computer vision syndrome Dry eye Visual fatigue

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhongshan Ophthalmic Center

    Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.